ClinicalTrials.gg
CompletedNCT03758339Updated Nov 29, 2018

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

A Phase 1 interventional study of tucatinib in Healthy, sponsored by Cascadian Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Cascadian Therapeutics Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2018, 8 years 9 months ago, and no results have been posted to the registry.
  • Registered 10 months after the study started (first participant enrolled Dec 2017, registered Nov 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib while it is still in the body. Healthy participants will get one dose of tucatinib by mouth. Patients will be monitored for 8-14 days after they take the dose of tucatinib.

Read the detailed description

This study will examine the absorption, metabolism, and excretion of tucatinib in healthy individuals. Participants will receive one oral dose of tucatinib and will be followed for 8-14 days after the dose is received.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Cascadian Therapeutics Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.

First submitted before Cascadian Therapeutics Inc. became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good health, determined by no findings from medical history, physical examination, 12-lead , vital signs measurements, or lab evaluations
  • (BMI) between 18 and 32 kg/m²
  • Weight between 50 and 100 kg
  • Females must be of non-
  • Males must agree to use

Exclusion criteria

Exclusion Criteria:

  • History of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
  • Any condition affecting drug absorption
  • History of or allergy to any drug compound, food, or other substance
  • History of alcoholism or drug/chemical abuse within 2 years
  • Use of prescription products within 28 days prior to check in
  • Use of tobacco- or nicotine-containing products within 3 months prior to check in
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Tucatinib

    Drug: tucatinib

Interventions

  • Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC) from time 0 to infinity (AUC[0-inf])

    PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles

    Time frame: Up to 14 days

  2. AUC from time 0 to last quantifiable concentration

    PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles

    Time frame: Up to 14 days

  3. Maximum observed concentration

    PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles

    Time frame: Up to 14 days

  4. Time of maximum observed concentration

    PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles

    Time frame: Up to 14 days

  5. Apparent terminal elimination half-life

    PK outcome parameter for tucatinib, ONT-993, and total radioactivity derived from the whole blood and plasma concentration-time profiles

    Time frame: Up to 14 days

  6. Apparent total clearance

    PK outcome parameter for tucatinib derived from the whole blood and plasma concentration-time profiles

    Time frame: Up to 14 days

  7. Apparent volume of distribution

    PK outcome parameter for tucatinib derived from the whole blood and plasma concentration-time profiles

    Time frame: Up to 14 days

  8. AUC[0-inf] plasma tucatinib/total radioactivity ratio

    AUC\[0-inf\] of plasma tucatinib relative to AUC\[0-inf\] of plasma total radioactivity

    Time frame: Up to 14 days

  9. AUC[0-inf] blood/plasma ratio

    AUC\[0-inf\] of whole blood total radioactivity to AUC\[0-inf\] of plasma total radioactivity

    Time frame: Up to 14 days

  10. Amount excreted in urine (Aeu)

    PK outcome endpoint of tucatinib, ONT-993, and total radioactivity derived from urine collections

    Time frame: Up to 14 days

  11. Cumulative Aeu

    PK outcome endpoint of tucatinib, ONT-993, and total radioactivity derived from urine collections

    Time frame: Up to 14 days

  12. Percentage excreted in urine (Feu)

    PK outcome endpoint of tucatinib and total radioactivity derived from urine collections

    Time frame: Up to 14 days

  13. Cumulative Feu

    PK outcome endpoint of tucatinib and total radioactivity derived from urine collections

    Time frame: Up 14 days

  14. Renal clearance

    PK outcome endpoint of tucatinib derived from urine collections

    Time frame: Up to 14 days

  15. Amount excreted in feces [Aef]

    PK outcome endpoint of total radioactivity derived from feces collection

    Time frame: Up to 14 days

  16. Cumulative Aef

    PK outcome endpoint of total radioactivity derived from feces collection

    Time frame: Up to 14 days

  17. Percentage excreted in feces [Fef]

    PK outcome endpoint of total radioactivity derived from feces collection

    Time frame: Up to 14 days

  18. Cumulative Fef

    PK outcome endpoint of total radioactivity derived from feces collection

    Time frame: Up to 14 days

Secondary outcomes

  1. Relative abundance of tucatinib and its metabolites eliminated in urine and feces

    Time frame: Up to 14 days

  2. Relative abundance of tucatinib and its metabolites in plasma

    Time frame: Up to 14 days

  3. Incidence of adverse events (AEs)

    Time frame: Up to 14 days

07

Study locations

1 site
  • Covance Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jan 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2018
First posted
Nov 29, 2018
StartActual
Dec 30, 2017
Primary completionActual
Jan 30, 2018
CompletionActual
Jan 30, 2018
Last update
Nov 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03758339
Responsible party
Sponsor
First posted
Nov 29, 2018
Start date
Dec 30, 2017
Primary completion
Jan 30, 2018
Completion
Jan 30, 2018
Last update
Nov 29, 2018

Study contacts

Alex Vo, PhD
study director · Cascadian Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion